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Abstract 
Therapeutic nanoparticles (NPs) are used in nanomedicine as drug carriers or 
imaging agents, providing increased selectivity/specificity for diseased tissues. The 
first NPs in nanomedicine were developed to increase the efficacy of known drugs 
displaying dose-limiting toxicity and poor bioavailability, and to enhance disease 
detection. Nanotechnologies have gained much interest owing to their huge potential 
for applications in industry and medicine. It is necessary to ensure and control the 
biocompatibility of the components of therapeutic NPs to guarantee that intrinsic 
toxicity does not overtake the benefits. As well as monitoring their toxicity in vitro, in 
vivo and in silico, it is also necessary to understand their distribution in the human 
body, their biodegradation and excretion routes, and dispersion in the environment. 
Therefore, a deep understanding of their interactions with living tissues and of their 
possible effects in the human (and animal) body is required for the safe use of 
nanoparticulate formulations. Obtaining this information was the main aim of the 
NanoTEST project, and the goals of the reports collected together in this special 
issue are to summarize the observations and results obtained by the participating 
research teams, and to provide methodological tools for evaluating the biological 
impact of NPs.
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Abstract 
Therapeutic nanoparticles (NPs) are used in nanomedicine as drug carriers or imaging agents, providing 
increased selectivity/specificity for diseased tissues. The first NPs in nanomedicine were developed to 
increase the efficacy of known drugs displaying dose-limiting toxicity and poor bioavailability, and to 
enhance disease detection. Nanotechnologies have gained much interest owing to their huge potential for 
applications in industry and medicine. It is necessary to ensure and control the biocompatibility of the 
components of therapeutic NPs to guarantee that intrinsic toxicity does not overtake the benefits. As well 
as monitoring their toxicity in vitro, in vivo and in silico, it is also necessary to understand their 
distribution in the human body, their biodegradation and excretion routes, and dispersion in the 
environment. Therefore, a deep understanding of their interactions with living tissues and of their possible 
effects in the human (and animal) body is required for the safe use of nanoparticulate formulations. 
Obtaining this information was the main aim of the NanoTEST project, and the goals of the reports 
collected together in this special issue are to summarize the observations and results obtained by the 
participating research teams, and to provide methodological tools for evaluating the biological impact of 
NPs. 
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Introduction: therapeutic nanoparticles in human medicine 
Progress in material science and physics has led to novel medical applications based on the intrinsic 
properties of nanomaterials. The term ‘nanomaterials’ covers materials with one, two or three dimensions 
in the nanoscale while nanoparticles (NP) are usually defined as systems for which all three dimensions are 
between 1-100 nm. The European Commission recently adopted the following definition: “A natural, 
incidential or manufactured material containing particles, in an unbound state or as an aggregate or as an 
agglomerate and where, for 50% or more of the particles in the number size distribution, one or more 
external dimensions is in the size range 1-100 nm. In specific cases and where warranted by concerns for 
the environment, health, safety or competitiveness the number size distribution threshold of 50% may be 
replaced by a threshold between 1 and 50%. [European Comission. Nanomaterials. 
http://ec.europa.eu/environment/chemicals/nanotech/index.htm].” However, no clear consensus has been 
established for a definition of NPs/nanomaterials among scientists (Kreyling et al. 2010).]. Different fields 
of nanotechnology apply slightly different definitions, especially concerning the size limit. The term 
nanoparticle in the field of nanomedicine encompasses particles with dimensions up to 1000 nm (Schütz et 
al. 2013a). NPs include solid core NPs, usually coated with polymers for colloidal stability and 
biocompatibility, whose thickness and charge can depend on environmental parameters and which cannot 
easily deform; and polymeric NPs, formed of polymer-copolymer systems, whose characteristics depend 
dramatically on environmental factors such as temperature, pH, ionic strength or medium quality, and 
which can easily deform to pass certain biological and physical barriers (Godin et al. 2010; Schütz et al. 
2013b).  
Thus molecules and nanoscale materials are manipulated to produce nanostructures that can interact with 
human cells, offering a range of new solutions for diagnosis and smart therapies. The 1st generation of 
therapeutic nanovectors relied on size effects, taking advantage of the enhanced retention and permeability 
(EPR) and avoidance of cell uptake; the 2nd generation nanovectors presently under evaluation rely on 
improved nanovector surfaces, and the 3rd generation will rely on smart nanovectors bearing 
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reconnaissance molecules aimed at  defined cell types for improved selectivity and cell uptake (Juillerat-
Jeannerat, 2006; Godin et al. 2011). Applications of nanoparticulate systems in medicine are aimed at 
improving diagnostic processes, increasing the efficacy of drugs known to have dose-limiting toxicity 
and/or poor bioavailability and biological stability, and improving the selectivity of drug delivery and of 
drug uptake by tissues (Schütz et al. 2013a,b). 
The first marketed therapeutic nanomaterial, approved in 1990, was Adagen® - a PEGylated -liposomal-
doxorubicin. Since then more than 40 nanoparticulate systems have been approved (Boulaiz et al. 2011; 
Schütz et al. 2013a; 2013b), mainly in the field of cancer treatment and predominantly represented by 
liposomal and micellar forms of widely used but poorly bioavailable anti-cancer agents. A variety of 
chemotherapeutic NPs are presently under pre-clinical development, in clinical use, or under advanced 
clinical trials (Juillerat-Jeanneret, 2006; Schütz et al., 2013a; Schütz et al., 2013b) (Table 1). 
After drug delivery, the most represented area of application is diagnostic imaging, including in most cases 
iron oxide-based NPs for magnetic resonance imaging (MRI) and gold NPs (Pablico-Lansigan et al. 2013). 
The third application is the preparation of therapeutic agents as nanosuspension (Patel et al. 2011; Figure 
1). Therapeutic NPs have evolved to include, for example, combination of imaging and therapy for 
diagnosis and thermal ablation of lesions, the so-called “theranostics” (Lammers et al. 2011). 
The choice of the materials composing therapeutic NPs depends not simply on biochemical/physical 
characteristics but also on whether biodegradation of the carrier is required, whether tissue reaction to the 
NPs can be avoided, and whether increased efficacy of the therapy can be achieved. Nanovectors are 
designed to afford protection of drugs against degradation (Godin et al. 2010; Godin et al. 2011), but 
controlled drug release is difficult to achieve and the interactions with living cells and tissues are poorly 
defined (Naahidi et al. 2013). If the biocompatibility of NPs cannot be ensured, potentially advantageous 
properties of therapeutic NPs may produce toxicological problems. It is important to identify the 
properties, to understand the mechanisms by which NPs interact with living systems and thus to 
understand exposure, hazards and possible risks of therapeutic NPs (Teow et al. 2011; Lai 2012; Klaine et 
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al. 2012).  
 
Addressing toxicity of therapeutic nanoparticles – the NanoTEST project 
The rapid growth in the use of nanomaterials in medicine has led to a concern about possible health risks. 
There is a serious lack of information available to predict health effects due to nanomaterial exposure 
(Pautler and Brenner 2010); in a regulatory context, nanoscale materials are still mostly treated in the same 
way as conventional chemicals and there is no consensus or clear nano-specific guideline for their 
regulation (Dusinska et al. 2009; 2011; 2012; 2013; Schrand et al. 2012). However, several scientific 
opinions (SCCS 2012; SCENIHR 2007; SCENIHR 2009; Scientific committees 2013), guidelines and 
specific European regulations and OECD guidelines such as for cosmetics (EU Directive 2009; OECD 
2012), food contact materials (EFSA 2009; EFSA 2011; OECD 2012), medical devices (OECD 2012; 
SCENIHR 2012) as well as the US Food and Drug Administration (FDA) regulations specifically address 
nanomaterials (FDA 2010; Duvall 2012). 
The NanoTEST project (www.nanotest-fp7.eu ) was one of the initiatives set up by European Commission 
to fill the knowledge gaps in this area, by studying the interactions of representative therapeutic 
nanomaterials with living cells, then developing and validating appropriate high-throughput toxicity testing 
protocols using in vitro models. Keeping in mind the 3 Rs (refine, reduce, replace animal testing), the 
testing strategy should reduce in vivo experiments. To achieve this, a comparison of in vitro and in silico 
with in vivo results is an important and critical aspect of the validation of in vitro and in silico methods. 
One of the main problems encountered in testing NPs for possible human hazard is the lack of appropriate 
standard protocols. 
The NanoTEST project started in April 2008. During the subsequent four years, twelve partne institutionrs 
were involved in the project, bringing together top scientists from ten European countries. Harmonisation 
has been the key element at every step, and we have used standard protocols and the same data templates 
in order to be able to compare results, as well as using NPs from same batch. NanoTEST consists of six 
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work packages (WPs): Characterization, In vitro studies, in vivo studies, (Q)SAR and PBPK modelling, 
Dissemination and Management (Figure 2). Close collaboration between the WPs has been of great 
importance in achieving our goals. 
A representative selection of nanomaterials was investigated. Commercial nanomaterials currently or soon 
to be applied in human medicine were chosen; Nanomagnetite coated with Na-oleate (OC-Fe3O4); 
Nanomagnetite uncoated (UC-Fe3O4), Red (Rhodamine) Fluorescent nanosilica 25nm and 50 nm (Fl-25 
SiO2 and Fl-50 SiO2), and Polylactic glycolic acid polyethylene oxide (PLGA-PEO). Titanium dioxide 
(TiO2 NP) was used as benchmark material. 
 
Physicochemical and biological characteristics of nanomaterials 
There is a general agreement that not only one, but several characteristics may influence the toxicity of 
NPs (Bouwmeester et al. 2011). The specific features and properties of NPs which differ from those of 
conventional chemicals include size, size distribution, surface, shape, chemical composition, 
bioavailability, solubility, agglomeration, dissociation and adsorption of biological molecules, all of which 
may have an impact on the ultimate toxicity of the NPs (Warheit et al., 2007; Handy et al. 2008a). NPs, 
including therapeutic NPs, have unique properties probably resulting from their high surface-to-volume 
ratio and surface reactivity (Stone et al., 2010). Within NanoTEST, the incorporation of physicochemical 
data on nanomaterials into a knowledge base was crucially important in order to investigate their potential 
biological effects. The selected NPs were exhaustively characterized prior to being applied as exposure 
material in toxicological tests, both as stock solutions and in the medium to be used for the specific 
cells/experiment. It was necessary to obtain comprehensive characterisations in addition to sound 
toxicological data in order to develop Structure-Activity models for toxicity predictions. Our aim was to 
provide a framework for assigning hazard categories to nanomaterials on the basis of screening tests and 
predictive modelling.  
Accurate and precise methods – both analytical (for characterisation of therapeutic NPs) and biological 
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(for efficacy and/or safety assessment) – as well as appropriate in vitro and in vivo models must be 
developed and validated in order to analyse factors such as solubility, biodegradability and dissolution of 
NPs in biological media, their interactions with living organisms, their reactivity and uptake by cells and 
tissues. Effects of therapeutic NPs depend on their potential for biological membrane penetration and their 
(intra-)cellular targets. Some information is already available; for solid-core therapeutic NPs, size of the 
core and the physicochemical characteristics of the surface polymers are the main determinants for tissue 
localization and cell effects of these nanovectors. The therapeutic efficacy and biological effects depend on 
the chemical components of these NPs, their solubility in a biological environment and their intra-cellular 
localization. Transport of NPs across biological barriers (cell membranes and cell-layer barriers) is very 
specific/selective and is as yet poorly understood (Handy et al 2008b). Some NPs are designed to 
overcome barriers, such as the blood brain barrier, but do not need to enter cells, while others need to enter 
cells to give the biological effects.  
The physico-chemical properties of NPs and the potential changes to NPs during absorption, distribution 
and metabolism in wildlife (Handy et al. 2008b) will equally affect the toxicity and fate of therapeutic NPs 
in the environment.  
Polymer-copolymer therapeutic NPs are very difficult to locate in living tissue. Some polymers and/or 
their degradation and biotransformation by-products may be cytotoxic over the long-term. However, the 
lack of clear clinical parameters as targets to monitor NP-related toxicity still limits the use of 
pharmacovigilance monitoring to collect data on the long term toxicity of NPs. Very little knowledge exists 
concerning the consequences of the uptake by cells or tissues of nanovectors, or the mechanisms of their 
degradation and elimination by cells, tissues and the whole body, even for the nanovectors in clinical use.  
Therapeutic NPs are different from NPs in ambient air pollution. However, the latter can inform about 
some of the characteristics that can lead to elevated hazards. Ambient particles are associated with a clearly 
increased risk for cardiovascular and pulmonary morbidity and mortality and the creation of reactive 
oxygen species (ROS) has repeatedly been proposed to be centrally involved in this response (Brook et al. 
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2010). A recent study of workers exposed to diesel exhaust suggested that functional groups such as 
reactive carbonyls promoted oxidative stress (Setyan et al. 2010). Thus, a potential strategy could be to 
evaluate the types of functional groups that are formed during the degradation of nanomaterials, and to 
compare them with a (yet to be established) library listing the oxidative stress potential of a wide range of 
functional groups. This would allow the identification of potentially critical materials even before they are 
created and tested in real cells and animals.  
 
Nanoparticles in the human body; uptake, distribution and excretion 
Basic questions concerning nanomaterials in the human body have yet to be adequately addressed 
including whether therapeutic NPs penetrate cells and tissues; how and where are they distributed inside 
the body; as well as how they are bio-degraded and excreted.  
The specific characteristics of nanomaterials compared to standard chemicals mean that it is not possible to 
transfer, without verification, the knowledge acquired with standard chemicals to nanoparticulate systems 
(Casals et al. 2010; Monopoli et al. 2011; Lundqvist et al. 2011; Milani et al. 2012). 
For drug delivery, NOs are administered orally, by inhalation, transdermally or parenterally (e.g. 
intravenous, intramuscular or subcutaneous). However, the main route of bio-distribution of therapeutic 
NPs in humans is the blood circulation, and it is necessary to consider the behaviour of these NPs in this 
organ. At the site of application and in the blood, a process called opsonization adds biomolecules onto the 
NP surface, forming a corona (casals et al. 2010; Lundqvist et al. 2011; Milani et al. 2012), the nature of 
which depends both on the surface characteritics of the NP and on the characteristics of the tissue. This 
coating of biomolecules will then determine the bio-distribution of the NPs in the patient, their behaviour 
in the body and the long-term consequences of their application.  
The properties of NPs and their reactivity may change when entering the human body, through surface 
functionalization by biological components, or through bio-degradation. NPs can be deposited in the 
different organs through blood and can accumulate in secondary target organs such as liver, spleen, brain, 
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kidney and heart although the exact amount is subject to debate (Oberdörster et al. 2004; Mills et al. 2006). 
Following access to the systemic circulation, particle half-life would normally be determined primarily by 
kidney elimination and ability to escape phagocytosis by the reticulo-endothelial system (liver, spleen, 
lymph nodes). For example, 36% silica particles (Ø 150 nm) after administration into rats' circulatory 
system were excreted with urine after four days. The remaining particles were accumulated in the kidneys 
and lungs, probably in the lung air sacs and kidney glomerulus (Borak et al. 2012). Silver nanoparticles (20 
and 200nm) were translocated from the blood to the main organs, mainly to liver and kidney 
(Dziendzikowska et al. 2012). Surface-modified PLGA NP were localized within the tissue parenchyma 
(brain, kidney, liver, spleen and lung)  (Tosi et al. 2010). NP characteristics such as size, surface charge 
and coatings are likely to affect trapping or targeting of tissues (Borm & Müller-Schulte 2006, Nemmar et 
al 2006, Hirn et al. 2011).  
We are only beginning to understand the dynamics and bioreactivity of NPs in complex biochemical 
matrices. Following their use and bio-transformation in humans and their excretion, their fate and 
behaviour in the environment are equally complex since these NPs have been biochemically modified by 
their passage through the human body, a process for which presently information is almost non-existent 
(Figure 3). The development of a life cycle-based evaluation of the impact of therapeutic NPs implies the 
development and validation of methods and tools for assessing the relationship between the characteristics 
of the NPs, their bio-distribution and bio-transformation in the human body, and environmental effects. 
The fate and toxicity issues presented by nanomaterials are highly important questions that have not yet 
been resolved, either scientifically or from a regulatory perspective. 
 
Toxicity testing 
In vivo pre-validation 
In vitro screening is increasingly used as part of hazard assessment. However, for understanding and 
interpreting results, in vivo validations are crucial. Experiments on animals were an integral part of the 
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NanoTEST project (Dusinska et al. 2009; Sebekova et al. 2013; Volkovova et al. 2013). Female rats were 
used as experimental animals for sensitivity considerations and the possibility of examining fetal exposure. 
The rats were exposed with three doses of NPs by intravenous injections. There was a single exposure at 
the beginning of the study with subsequent sacrifice after 1, 2, 3 and 4 weeks. The effects of exposure to 
NPs were studied in the heart/aorta, liver, lung, brain, blood, spleen, bone marrow. Gross pathological and 
histopathological examinations were made according to the guidelines of OECD (433). In parallel with the 
in vitro screening, the following biomarkers were followed; cardiotoxicity, hepatotoxicity, nephrotoxicity, 
neurotoxicity, damage in lung tissue cells, genotoxicity, oxidative stress, immunotoxicity and routine basic 
haematological examinations undertaken at sacrifice.  
The state-of-art when the project started did not provide information about standard procedures used for 
testing nanomaterials, and so the information gained from in vivo experiments is an important contribution 
for assessing nanomaterial toxicity. Strategically it was most important to compare and validate the in vitro 
results with in vivo. It would be too ambitious to compare all the endpoints mentioned above, and the focus 
was therefore to assess the effects of NPs on genotoxic and immune response with the aim to compare 
results of in vitro findings with in vivo findings in rats. A panel of immune biomarkers applicable in both 
in vitro and in vivo models was used for the assessment of possible immunotoxic effects of NPs. The same 
assays were performed in vitro in human peripheral blood and in peripheral blood of rats exposed in vivo 
to TiO2 and OC-Fe3O4 NPs. 
 
In vitro screening 
Dependent on the route of exposure, various organs, tissues and cells can be exposed to NPs. To reduce 
amount of tests, certain organs were selected and representative cell lines derived from these organs were 
defined. These were chosen on the basis of the most likely cells to be affected, depending on the exposure 
route. In nanomedicine the most likely route is intravenous injection, where first to be affected are the 
plasma and circulating cells, the cells of the vascular wall (e.g. brain-derived endothelial cells), followed 
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by the liver, the lung, the placenta, the brain and the kidneys. Inhalation will affect the epithelial cells of 
the bronchi and the alveolae and immune cells of the lung surface. Oral exposure will affect cells of the 
stomach and the colon.  
As the activity of NPs is likely to involve specific toxicity endpoints, the project focused on the cross-
cutting areas of cellular toxicity, uptake, transport through barriers, oxidative stress, inflammation, 
immunotoxicity and genotoxicity. An illustration of the structure of in vitro screening is given in Figure 2. 
The main objectives of the in vitro screening were; to evaluate the impact on specific cell functions of 
exposing cells or tissues of different phenotypes to NPs of various chemical composition, size and surface 
characteristics; and to define objective markers of cell reactions elicited with the selected NPs, which 
would serve as reference markers when studying novel nanomaterials. A better understanding of how 
properties of NPs determine their interactions with cells, tissues and organs in exposed humans and 
animals is a considerable scientific challenge but one that must be addressed if there is to be safe and 
responsible use of biomedical NPs. This process involved the development and adaptation of reliable and 
standardized in vitro assays and protocols to ensure that the potential risks of NPs are properly assessed. 
These assays and protocols were standardised across the Consortium through the use of the same NP dose 
range, exposure time-points and extent of cell confluency at time of exposure. Results from the in vitro 
screening were used to determine the assays most suitable for automation and to refine the in vivo 
experiments required. 
 
Modelling 
Using computerized tools for assessing hazard and risk may be valuable for screening and gives an 
opportunity to save time and resources compared with experimental studies. These approaches must be 
validated, adequately explained and made accessible to peer-review to be of any value for risk assessment 
and regulatory use (Nel et al. 2012). Structure-activity modelling is based on the assumption that similar 
chemical structures exhibit similar biological activities, thus enabling development of mathematical 
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models relating chemical structure to activity. The use of Structure-Activity models, such as (Q)SARs and 
chemical category approaches, are well-established approaches for predicting the properties and activities 
of chemicals; however, research on descriptors which encode the specific reactivity of NPs is still scarce. 
Obviously, the development of Structure-Activity models requires a whole knowledge of properties 
affecting the toxicity of NPs and very few studies have attempted to develop these models for NPs (Bosi et 
al. 2004). In NanoTEST one of the aims was therefore to identify descriptors relevant for the 
experimentally determined toxicitity endpoints and suitable for modelling from the available data. For that 
purpose, expert knowledge as well as different “variable selection” statistical approaches were used. The 
selected descriptors in addition to the experimentally determined physicochemical properties (size, surface 
area, solubility etc.) were the starting point to develop Structure-Activity models using various statistical 
multivariate data analysis techniques.  
Extrapolation modelling such as Physiologically Based Pharmacokinetic (PBPK) can be used to equate 
tissue-medium concentrations from toxicity testing with tissue doses expected in humans (Nel et al. 2012). 
The fate of nanomaterials in the body was studied using PBPK modelling approaches, by implementing 
two levels of refinement, corresponding to lumped parameter models and advanced mechanistic 
(distributed parameter) models. The former consisted of a simple compartment-based modelling approach 
and the latter model was based on computational fluid-particle dynamics to simulate detailed deposition in 
the respiratory or the cardiovascular system. The use of computational methods for deposition and 
behaviour in the lungs or the cardiovascular system can replace in vivo toxicokinetic tests and therefore 
significantly contribute to alternative testing methods.  
 
Impact assessment 
The tools used in assessing the risks that chemicals in general pose to people and the environment include 
toxicology, molecular biology, chemistry, high-throughput technologies and computer science; they are 
applied ultimately to develop predictive models, and the toxicological evaluation is used by regulatory 
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agencies to provide recommendations for health and safety. However, while the technologies have been 
developed and validated for many years for chemicals, the process is much newer with NPs, and there is a 
need to develop evaluation processes and validation protocols. The factors to consider when assessing the 
use of NPs in nanomedicine include their size, exposure scheme, dose, the population involved and the 
length of time of exposure (chronic versus acute exposure). With therapeutic NPs in particular, there are 
substantial gaps in our knowledge of the behaviour of these NPs in humans (Figure 4), and the life-cycle 
evaluation of their impact is far from complete. The difficulty facing the regulatory agencies is the need to 
regulate emerging technologies at the same time as research is progressing, in the absence of a full 
scientific understanding of which parameters to control and review. 
Novel technologies based on NPs will clearly benefit patients and will have a direct impact on health and 
the quality of life in the future. They have the potential to improve health monitoring, diagnosis, treatment, 
and can contribute to the repair of tissues and organs to arrest the progression of disease. It is also expected 
that nanomedicine will play a role in “personalized medicine”. But the beneficial effects must not be at the 
price of increased risk for the patients; the new technologies must be safe and sustainable, for human 
health and the environment. 
Life cycle impact assessment is a formalised concept for evaluating the relative biological and 
environmental effects of a product in general (ISO 2006a; ISP 2006b). Its application to nanomaterial is 
under validation. All stages of a nanoproduct life cycle – the production, transport, use and final disposal 
of the product(s) – need to be considered (Som et al. 2010), taking into account the by-products of their 
bio-transformation in the human body. A thorough impact assessment will facilitate the process of decision 
making by industry, research institutions and regulatory agencies. It will also help to identify gaps in 
knowledge and to prioritise topics for further research.  
However, the experimental approaches to be used must first be defined. Presently it is not clear how in 
vitro data can predict in vivo  effects. It is necessary to evaluate whether in vitro toxicological approaches, 
with their limitations such as the lack of information on the uptake and distribution of NPs in vivo, are 
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relevant. In vitro studies can provide information concerning potential toxicity and dose dependency, and 
fundamental knowledge on biological targets and effects. The importance of particle characterization, not 
only as prepared, but also as bio-modified in biological matrices has also to be emphasised.  
The knowledge gaps identified include a lack of knowledge on appropriate/optimal metrology, biological 
mechanisms and modes of action, toxico-kinetics (biopersistence), realistic exposure levels in relation to 
increasingly sensitive methods to detect effects of NPs, standardised testing protocols, transport (and/or 
indirect signalling) across biological barriers, and quantitative in vitro-in vivo extrapolation of the effects 
of NPs. NPs often display different chemical, physical, and biological characteristics from those of the 
bulk form of the same substance, highlighting the need for specific nano-policies (Baun and Hansen 2008). 
However, for many NPs, production volumes (by mass) are well below the threshold necessitating the 
provision of data relating to health and safety (Malkiewicz et al. 2009).  
The current guidelines for testing medicines from the EU medicines agency do not require any nano-
specific protocols, raising concerns that hazards can be missed or overestimated. However, a focused 
review of nanomedical patents and published literature (Schütz et al. 2012) to assess the incidence and type 
of safety data being reported for nanomedicines under development showed an encouraging level of 
toxicity evaluation. 
Just as with the toxicity testing of therapeutic NPs described above, there is also a concern about 
monitoring public health in the environment and there is a lack of agreed protocols to measure human 
exposure or effect (hazard) in non-clinical settings.  
 
Clinical Trial Authorisations and NanoTEST 
Current regulatory procedures for approving new medicines (and those for medical devices) also apply to 
nanomaterials. The overarching process of conducting a clinical trial with a medicine intended for human 
use is covered by the Clinical Trials Directive (DIRECTIVE 2001/20/EC) which sets out the 
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implementation of good clinical practice for such trials, and various codes relating to medicinal products 
for humans (e.g., DIRECTIVE 2004/27/EC). In addition regulation EC number 726/2004 lays down the 
procedure for the authorization and supervision of medicinal products and this involved establishing the 
European Medicines Agency with some oversight of national level authorities within Europe 
(REGULATION (EC) No 26/2004). Clearly, these regulations set out a well defined process which must 
be followed, and (until scientific evidence shows we need something different) these regulations apply just 
as equally to nanomedicines as the fundamental purpose of the regulations is the same for all medicines. 
Outside the European Union, regulations tend to be set at national level. For example, in the United States 
the FDA  Code of Federal Regulations 21 sets out the provisions for drugs intended for human use (FDA, 
2012); but these national level regulations do consider the principle of international harmonization when 
setting their rules. There are some key foundations on which the approval of any new medicine is based; 
(i) demonstrating that the new product works and is effective for its intended clinical use; (ii) if it is 
replacing an existing medicine the product should be better or more effective than the existing product, and 
(iii) that the new product is safe, or safer than the old one. NanoTEST and the mammalian research in the 
EU nanosafety cluster is contributing data mainly in the pre-clinical phase where proof of principle 
(efficacy and mode of action) and safety should be established for the candidate medicine. The overall 
clinical trials process including the drug registration and pharmacovigilence during its initial use is very 
expensive (e.g., typically 10-15 years from idea to medicine, circa 350 million Euros). This represents a 
big financial investment for the drug company and the in vitro and in silico modelling in the early stages is 
therefore crucial to both the scientific and financial investment into a prospective medicine. Making 
decisions on drug development requires confidence in the methodology as well as results of the in silico 
and in vitro work. The NanoTEST project goes some considerable way to providing the evidence-base that 
shows that these approaches can and do work for therapeutic NPs.  
The next step for the drug company is to extrapolate from in vitro to in vivo (discussed above) and from a 
regulatory perspective the routine requirement is to include at least two relevant species where the test 
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animals are expressing the target receptors for the drug of interest. The latter is problematic for 
nanomaterials in that the material may not be intended for the classic receptor-mediated drug response, or 
there may be concerns that the NP is immunogenic (Dobrovolskaia and McNeil, 2007). The regulations 
also require that the route of uptake, frequency of dosing, formulation, concentration and administration 
site must be related to the expected use in humans, and in NanoTEST for example, experiments are 
included on intravenous injections of NPs.  
After successful animal studies, the prospective medicine is evaluated for safety in a small group of 
healthy human volunteers. For therapeutic NPs the problems of jumping the species barrier to man are the 
same as for conventional medicines, including; the need to account for differences in body sizes/blood 
volumes between laboratory rodents, marmosets, and humans; correcting for mass effects on drug 
metabolism with mass specific metabolic rates; for oral medicines dealing with the changes in gut 
chemistry/nutrition as one moves from animals to man, as well as differences in blood chemistry between 
species. For conventional medicines these extrapolations across species are routine and the industry makes 
use of look-up tables for blood volume differences and distribution times of soluble substances, species 
specific metabolic rates, etc. However, these data in many cases do not exist for NPs and (for example) 
given the aggregation properties of NPs we should not assume that standard look-up tables of blood 
volume will tell us anything about the predicted concentration in humans – just multiplying up the blood 
volumes across species is not a safe assumption for NPs. NanoTEST has incidentally captured some of this 
required data during in vivo experiments. A complete histopathology on the animals is also required before 
a first dose into man can be given, and some of the data in NanoTEST show organ pathologies that are also 
well known for other chemicals, adding to confidence in these kinds of data for the industry.  
The regulations also require that the safety trials in human volunteers (i.e., phase I studies) demonstrate 
that the medicine has no or limited adverse effects on patients (no SAE, serious adverse event, or serious 
adverse drug reaction, ADR), and gives measurable dynamics (e.g., in the blood) that enable practical 
considerations such as likely margins of safety for prescribing errors/accidental overdose in the real world 
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(large therapeutic index). The problem for nanomaterials is to know precisely what to put in place for 
patient care should the first dose into man go wrong. The usual routine of monitoring vital signs, having a 
team on stand-by to deal with cardiac arrest, etc. (i.e., the obvious clinical obligations to ensure volunteer 
survival) will always be in place, but anticipating the unexpected is the real challenge for NPs and there are 
regulations that say “suspected unexpected adverse reactions” should be reported to the authorities. 
Typically, unexpected adverse reactions can be inferred from the fine details in the pre-clinical data, often 
relying on very experienced staff piecing together small details from animal and in vitro studies as possible 
adverse effects in the first human study. So for example, if the animal histopathology showed some 
changes in the anatomy of the thyroid, then it might be worth measuring metabolic rate or circulating 
thyroxine levels in humans as a potential adverse effect that may appear, even if it not related to the mode 
of action of the NP. It is the absence of such logic(s) and detailed measurements in the patient that usually 
leads to unexpected catastrophic outcomes. Thus, both new ways of thinking and comprehensive data sets 
need to be developed for NPs. NanoTEST provides relevant data from pre-clinical investigations, but we 
have yet to detail the cross-talk between body systems for NPs in order to look for the unexpected 
outcome. In addition, given the unusual physico-chemical properties of NPs, perhaps more weight should 
be given to the pre-clinical data sets, and more time spent using the data to ponder the unexpected before 
deciding the dose and clinical care plan for the very first human to receive a new drug.   
 
Conclusions and remarks 
Appropriate risk assessment in relation to health and safety of NPs used in medicine is essential, in order 
to ensure ethical, societal and regulatory acceptance, and public confidence. Many knowledge gaps 
concerning the health impact assessment of therapeutic NPs must be filled. There is presently no consensus 
on the most suitable toxicity tests, models for exposure assessment, and standardized testing strategies to 
evaluate possible hazards of therapeutic NPs for human health. Long-term effects of chronic exposure in 
humans of these NPs must be assessed. Tools for detecting NPs in situ must be developed for many of 
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these therapeutic NPs. Bio-transformation of therapeutic NPs in the human body, their interaction with 
biological systems as well as adsorption, distribution, metabolism, transformation, degradation and 
excretion (ADME) in living systems should be studied in conjunction with a characterisation of NPs in 
terms of size distribution, surface properties, biopersistance, and stability of original and modified NPs in 
different biological media.  
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List of Tables  
Table 1: A few examples of therapeutic nanoparticles  
Drug  Polymer platform Biological advantages 
Doxorubicin PEG-liposomes chitosan, PLGA, 
etc 
Decreased cardiotoxicity 
5-fluorouracil PEG-dendrimers, PEG-micelles Increased half-life 
Tamoxifen PEG-nanospheres Increased half-life and solubility 
Cisplatin/carboplatin Liposomes Increased half-life  
Methotrexate PEG-copolymers, folic acid-
PANAM 
Decreased toxicity 
Camptothecins Liposomes Increased solubility and stability  
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Figure 1. Examples of therapeutic NPs in clinics: MRI contrasts agents, mainly represented by iron oxide 
NPs; nanosuspensions of therapeutic drugs, for example inhaled corticoids; and PEG-gylated liposomal 
anti-cancer chemotherapeutics.  
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Figure 2. Work package structure of the NanoTEST project and structure of in vitro screening programme; 
cross-cutting topics cover all investigated organs 
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Figure 3. Knowledge gaps in the life cycle of therapeutic NPs in humans 
 
 
 
Figure 4. Overview of gaps in our knowledge for risk assessment of therapeutic NPs 
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